PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 65 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $212,000 | -9.0% | 10,867 | -17.6% | 0.02% | -8.0% |
| Q2 2020 | $233,000 | +65.2% | 13,189 | -23.0% | 0.02% | +108.3% |
| Q1 2020 | $141,000 | +18.5% | 17,122 | +1.0% | 0.01% | +20.0% |
| Q4 2019 | $119,000 | -46.4% | 16,947 | -8.4% | 0.01% | -47.4% |
| Q3 2019 | $222,000 | -9.4% | 18,511 | -8.6% | 0.02% | -9.5% |
| Q2 2019 | $245,000 | -5.4% | 20,244 | -1.7% | 0.02% | 0.0% |
| Q1 2019 | $259,000 | +46.3% | 20,599 | -21.8% | 0.02% | +50.0% |
| Q4 2018 | $177,000 | -50.1% | 26,335 | -29.4% | 0.01% | -36.4% |
| Q3 2018 | $355,000 | +50.4% | 37,299 | +6.2% | 0.02% | +57.1% |
| Q2 2018 | $236,000 | – | 35,133 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pharmstandard International S.A. | 750,632 | $7,724,000 | 26.59% |
| BVF INC/IL | 2,617,967 | $26,939,000 | 2.37% |
| GREAT POINT PARTNERS LLC | 982,449 | $10,109,000 | 1.58% |
| Alambic Investment Management, L.P. | 65,128 | $670,000 | 0.53% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,243,202 | $23,083,000 | 0.14% |
| ALGERT GLOBAL LLC | 44,477 | $458,000 | 0.10% |
| Monashee Investment Management LLC | 42,945 | $442,000 | 0.09% |
| Tekla Capital Management LLC | 219,042 | $2,254,000 | 0.08% |
| Spark Investment Management LLC | 138,800 | $1,428,000 | 0.08% |
| OXFORD ASSET MANAGEMENT LLP | 187,653 | $1,904,000 | 0.04% |